tickerade

@tickerade.bsky.social

1 day ago

$RCKT soars as FDA approves Kresladi for pediatric patients with severe LAD-I

tickerade

@tickerade.bsky.social

1 day ago

Today’s most trending tickers with positive sentiment (last 24h):

$SPY: 41
$META: 16
$VIX: 14
$ARTL: 13
$RCKT: 11
$SPX: 10
$NXXT: 9
$NVDA: 9
$VVOS: 7
$MSFT: 7
$ASTS: 6
$NBIS: 6
$NFLX: 6
$MU: 5
$VSA: 5
$IPO: 4
$BTC: 4
$DHS: 4

Stock Master

@stockmaster70.bsky.social

2 days ago

📢 Stocks Trending NOW: #META #CRWD #U #RDDT #ONCO #ARTL #VSA #RCKT #BROS #NFLX

StockTitan

@stocktitan.net

2 days ago

FDA approves first gene therapy for children with severe LAD-I The treatment targets a rare immune disorder tied to early-childhood mortality. Rocket also received a Rare Pediatric Disease Priority Review Voucher.

#RCKT Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

www.stocktitan.net/news/RCKT/rocket-pharmac...

StockTitan

@stocktitan.net

1 month ago

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress Dosing of additional patients for the Phase 2 study of RP-A501 for Danon disease anticipated in the first half of 2026. In August 2025, Rocket disclosed that the U.S. Food and Drug Administration’ s lifted the clinical hold on the Company’ s pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease in under three months. Per agreement with the FDA, three...

#RCKT Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

www.stocktitan.net/news/RCKT/rocket-pharmac...

StockTitan

@stocktitan.net

4 months ago

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q3 2025 results and program updates on November 6, 2025. Cash, cash equivalents and investments were $222.8M, which the company expects will fund operations into the second quarter of 2027 (excluding any Priority Review Voucher proceeds).Regulatory and clinical milestones include FDA acceptance of a resubmitted BLA for KRESLADI with a PDUFA date of March 28, 2026, FDA agreement to resume the pivotal Phase 2 trial of RP-A501 for Danon disease with three additional patients dosed at 3.8×10^13 GC/kg in 1H 2026, and ongoing development of RP-A601 and RP-A701. Leadership additions were announced for CMO, COO, and Chief Commercial & Medical Affairs.

#RCKT Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

www.stocktitan.net/news/RCKT/rocket-pharmac...

StockTitan

@stocktitan.net

5 months ago

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) Rocket Pharmaceuticals, Inc., a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration has accepted the resubmission of the Biologics License Application for KRESLADI™, a lentiviral vector- based...

#RCKT Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

www.stocktitan.net/news/RCKT/rocket-pharmac...

Thiard News@F4F

@newsen.bsky.social

6 months ago

Kuehn Law Investigates Breach of Fiduciary Duties at Rocket Pharmaceuticals Kuehn Law is urging shareholders of Rocket Pharmaceuticals to come forward regarding potential breaches of fiduciary duties by company executives.

Kuehn Law Investigates Breach of Fiduciary Duties at Rocket Pharmaceuticals #USA #New_York #Kuehn_Law #Rocket_Pharmaceuticals #RCKT

StockTitan

@stocktitan.net

7 months ago

Clinical Hold Lifted: Rocket Pharmaceuticals Cleared to Resume Groundbreaking Danon Disease Gene Therapy Trial FDA authorizes resumption of RP-A501 Phase 2 trial with adjusted 3.8E13 GC/kg dose. Study to continue with modified immunomodulatory regimen, targeting 12 patients total for rare genetic heart condition.

#RCKT Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

www.stocktitan.net/news/RCKT/rocket-pharmac...

Thiard News@F4F

@newsen.bsky.social

7 months ago

Class Action Lawsuit Filed Against Rocket Pharmaceuticals: Key Details for Investors Pomerantz Law Firm announces a class action lawsuit against Rocket Pharmaceuticals. Key deadlines are approaching for affected investors to take action.

Class Action Lawsuit Filed Against Rocket Pharmaceuticals: Key Details for Investors #United_States #New_York #Pomerantz_LLP #Rocket_Pharmaceuticals #RCKT

Thiard News@F4F

@newsen.bsky.social

7 months ago

Legal Action Initiated Against Rocket Pharmaceuticals Over Misleading Statements to Investors Rocket Pharmaceuticals faces a class action lawsuit for allegedly misleading investors about clinical trial risks. Affected shareholders encouraged to participate.

Legal Action Initiated Against Rocket Pharmaceuticals Over Misleading Statements to Investors #USA #New_York #Gross_Law_Firm #Rocket_Pharmaceuticals #RCKT

Thiard News@F4F

@newsen.bsky.social

7 months ago

Investors Urged by Faruqi & Faruqi Regarding Rocket Pharmaceuticals Class Action Lawsuit Deadline Faruqi & Faruqi informs investors of a critical class action lawsuit deadline against Rocket Pharmaceuticals, urging affected shareholders to act before August 11, 2025.

Investors Urged by Faruqi & Faruqi Regarding Rocket Pharmaceuticals Class Action Lawsuit Deadline #New_York #Faruqi_&_Faruqi #Rocket_Pharmaceuticals #RCKT

Thiard News@F4F

@newsen.bsky.social

7 months ago

Join the Class Action Against Rocket Pharmaceuticals Before the Deadline Levi & Korsinsky, LLP invites investors in Rocket Pharmaceuticals to join a class action lawsuit regarding securities fraud. The deadline is August 11, 2025.

Join the Class Action Against Rocket Pharmaceuticals Before the Deadline #USA #New_York #Levi_&_Korsinsky #Rocket_Pharmaceuticals #RCKT

StockTitan

@stocktitan.net

7 months ago

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q2 2025 financial results and strategic updates, highlighting a significant organizational restructuring and pipeline prioritization. The company is focusing on its AAV cardiovascular gene therapy platform, particularly RP-A501 for Danon disease, RP-A601 for PKP2-ACM, and RP-A701 for BAG3-DCM.Key financial metrics include cash position of $271.5M with runway into Q2 2027, Q2 R&D expenses of $42.7M (down from $46.3M YoY), and net loss of $68.9M ($0.62 per share). The company announced a 30% workforce reduction expected to lower 12-month cash burn by nearly 25%.Notable developments include FDA RMAT designation for RP-A601, Fast Track designation for RP-A701, and ongoing FDA review of KRESLADI™ for LAD-I treatment. The RP-A501 Danon disease trial remains on clinical hold following a serious adverse event.

#RCKT Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

www.stocktitan.net/news/RCKT/rocket-pharmac...

Thiard News@F4F

@newsen.bsky.social

7 months ago

Join the Class Action Suit Against Rocket Pharmaceuticals to Seek Financial Recovery Attention Rocket Pharmaceuticals investors: The Gross Law Firm invites you to join the class action suit for recovery of losses suffered due to misleading statements and failures to disclose crucial information.

Join the Class Action Suit Against Rocket Pharmaceuticals to Seek Financial Recovery #United_States #New_York #Class_Action #Rocket_Pharmaceuticals #RCKT

Thiard News@F4F

@newsen.bsky.social

7 months ago

Berger Montague Notifies Rocket Pharmaceuticals Investors About Class Action Deadline on August 11, 2025 Investors in Rocket Pharmaceuticals are urged to pursue a securities fraud lawsuit before the impending August 11, 2025 deadline, following serious allegations.

Berger Montague Notifies Rocket Pharmaceuticals Investors About Class Action Deadline on August 11, 2025 #USA #Philadelphia #Berger_Montague #Rocket_Pharmaceuticals #RCKT

Thiard News@F4F

@newsen.bsky.social

7 months ago

Rocket Pharmaceuticals Investors Urged to Act Before Deadline for Securities Fraud Lawsuit Compensation Rocket Pharmaceuticals, Inc. investors have until August 11, 2025, to join a class action lawsuit regarding significant losses, potentially recovering compensation without upfront fees.

Rocket Pharmaceuticals Investors Urged to Act Before Deadline for Securities Fraud Lawsuit Compensation #United_States #New_York #Securities_Fraud #Rocket_Pharmaceuticals #RCKT

Thiard News@F4F

@newsen.bsky.social

7 months ago

Opportunity for Rocket Pharmaceuticals Investors to Lead Securities Fraud Lawsuit Against RCKT Investors in Rocket Pharmaceuticals who suffered losses are now given the chance to lead a securities fraud class action lawsuit against the company. Take action now.

Opportunity for Rocket Pharmaceuticals Investors to Lead Securities Fraud Lawsuit Against RCKT #USA #Los_Angeles #Securities_Fraud #Rocket_Pharmaceuticals #RCKT

Thiard News@F4F

@newsen.bsky.social

7 months ago

Rocket Pharmaceuticals Faces Securities Lawsuit Over Alleged Fraudulent Misleading Statements to Investors Rocket Pharmaceuticals, Inc. is currently being sued for alleged securities law violations, impacting numerous investors. Important information here.

Rocket Pharmaceuticals Faces Securities Lawsuit Over Alleged Fraudulent Misleading Statements to Investors #USA #New_York #Levi_&_Korsinsky #Rocket_Pharmaceuticals #RCKT

Thiard News@F4F

@newsen.bsky.social

7 months ago

Rocket Pharmaceuticals Faces Lawsuit Over Alleged Securities Violations: Important Update for Investors Rocket Pharmaceuticals, Inc. is facing a lawsuit for alleged securities law violations. Investors are urged to connect with The Gross Law Firm for guidance and updates.

Rocket Pharmaceuticals Faces Lawsuit Over Alleged Securities Violations: Important Update for Investors #United_States #New_York #Gross_Law_Firm #Rocket_Pharmaceuticals #RCKT

Thiard News@F4F

@newsen.bsky.social

7 months ago

Investors of Rocket Pharmaceuticals Can Take Lead Role in SEC Fraud Lawsuit Over Safety Claims Investors who suffered significant losses with Rocket Pharmaceuticals are encouraged to join a class action suit, spearheaded by Faruqi & Faruqi, LLP. Act before the deadline!

Investors of Rocket Pharmaceuticals Can Take Lead Role in SEC Fraud Lawsuit Over Safety Claims #United_States #New_York #Faruqi_&_Faruqi #Rocket_Pharmaceuticals #RCKT

Thiard News@F4F

@newsen.bsky.social

7 months ago

Rocket Pharmaceuticals Investors Advised to Contact Legal Team About Rights Before August 2025 Deadline Shareholders of Rocket Pharmaceuticals, Inc. are urged to reach out to The Gross Law Firm before August 11, 2025, to understand their legal rights related to recent company disclosures.

Rocket Pharmaceuticals Investors Advised to Contact Legal Team About Rights Before August 2025 Deadline #United_States #New_York #The_Gross_Law_Firm #Rocket_Pharmaceuticals #RCKT

Thiard News@F4F

@newsen.bsky.social

8 months ago

Rocket Pharmaceuticals Faces Class Action Lawsuit Due to Securities Law Violations Rocket Pharmaceuticals, Inc. is facing a class action lawsuit over securities fraud. Investors are encouraged to reach out to Levi & Korsinsky for assistance before August 11, 2025.

Rocket Pharmaceuticals Faces Class Action Lawsuit Due to Securities Law Violations #USA #New_York #Levi_Korsinsky #Rocket_Pharmaceuticals #RCKT

Thiard News@F4F

@newsen.bsky.social

8 months ago

Rocket Pharmaceuticals Faces Legal Action for Alleged Securities Violations: Shareholders Urged to Act Shareholders of Rocket Pharmaceuticals are advised to engage with The Gross Law Firm regarding potential securities law violations affecting their investments.

Rocket Pharmaceuticals Faces Legal Action for Alleged Securities Violations: Shareholders Urged to Act #USA #New_York #Securities_Law #Rocket_Pharmaceuticals #RCKT

Thiard News@F4F

@newsen.bsky.social

8 months ago

Rocket Pharmaceuticals Investors Alerted to Class Action Lawsuit, Deadline Approaches for Lead Plaintiff Levi & Korsinsky notifies Rocket Pharmaceuticals investors about a class action lawsuit with a lead plaintiff deadline of August 11, 2025. Here's what you need to know.

Rocket Pharmaceuticals Investors Alerted to Class Action Lawsuit, Deadline Approaches for Lead Plaintiff #United_States #New_York #Class_Action #Rocket_Pharmaceuticals #RCKT

Thiard News@F4F

@newsen.bsky.social

8 months ago

Class Action Lawsuit Filed Against Rocket Pharmaceuticals: Investors Urged to Act Quickly The Gross Law Firm has announced a class action lawsuit against Rocket Pharmaceuticals, urging affected investors to take action by the upcoming deadline.

Class Action Lawsuit Filed Against Rocket Pharmaceuticals: Investors Urged to Act Quickly #USA #New_York #Gross_Law_Firm #Rocket_Pharmaceuticals #RCKT

StockTitan

@stocktitan.net

8 months ago

Rocket Pharmaceuticals Slashes Workforce 30%, Shifts Focus to Massive Cardiovascular Market Opportunity Strategic shift to cardiovascular gene therapy platform targets 100,000+ patients. Company extends cash runway to 2027 through 25% cost reduction. See full details.

#RCKT Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs

www.stocktitan.net/news/RCKT/rocket-pharmac...